3 Biotechs on the Move

Harry Boxer  |

Three biotechs, along with recent IPO Pinterest, are among our four charts to watch today.

G1 Therapeutics, Inc.  (GTHX) jumped $4.75, or 24%, to $24.50 on 2.2 million shares Tuesday. The move, on over 5 times its average volume, came on news of encouraging data from the company's phase 2 study of its trilaciclib treatment for metastatic triple-negative breast cancer. The stock has next resistance at its May high at $27.90, a move through which could take it to $30.

Iovance Biotherapeutics, Inc.  (IOVA) gained 45 cents to $22.40 on 2.3 million shares. IOVA was among cancer-therapy stocks moving on Monday's news that Pfizer Inc. will acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion. The stock is near the top of the rising channel it's been in since gapping up a month ago and could see some consolidation before its next move, with a target of $28.

Nektar Therapeutics  (NKTR) popped $1.47 to $35.17 on 1.1 million shares Tuesday on no news from the developer of drug candidates for cancer, auto-immune disease, and chronic pain. The stock is in a mini-base pattern and needs to get through its recent double-top at $35.80. A move through there could get it to $38.75 next.

Pinterest, Inc.  (PINS) rallied 95 cents to $28.80 on 8.7 million shares Tuesday. The move came on no news from the online discovery service, but followed bullish comments and coverage initiation Monday by a Wedbush analyst. After exploding out of its recent IPO and then pulling back, the stock is on the move again. Next target would be the lateral resistance level at about $31.

See Harry's video chart analysis on these stocks and others:

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change






INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup

Equities.com Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.